Intralytix, Inc. is a biotechnology company focused on the discovery, production and marketing of bacteriophage-based products to control bacterial pathogens in environmental, food processing, and medical settings.
Bacteriophages (bacteria-eater: from the Greek phago meaning "to eat" or "to develop at the expense of") are the most abundant microorganisms on earth. They are the natural enemies of bacteria. Lytic bacteriophages can very effectively kill their targeted specific bacteria without affecting anything else, ensuring an unprecedented level of safety for an antimicrobial.
In The News
Intralytix phage-based Shigella tech backed by FDA
Intralytix Inc's product targeting Shigella has received GRAS (Generally Recognized As Safe) recognition from the US Food and Drug Administration (FDA).
Intralytix, Inc. and BioPhage Therapeutics Limited partner to develop topical bacteriophage treatments of human wounds infected with S. aureus.
Intralytix, Inc. announced today that the Company is partnering with BioPhage Therapeutics Limited to develop and commercialize topical bacteriophage treatments of human wounds infected or colonized with S. aureus.
Intralytix Receives FDA Regulatory Clearance for Phage-Based Shigella Technology
Intralytix, Inc. announced today that its latest food safety product, ShigaShield™, has received GRAS (Generally Recognized As Safe) recognition from the Food and Drug Administration (FDA)
Intralytix, Inc. and Ferring Pharmaceuticals partner to develop bacteriophage treatments
Ferring Pharmaceuticals is partnering with Intralytix, Inc to develop and commercialise bacteriophage-based treatments for conditions associated with the presence of pathogenic bacteria or dysbiosis of the microbiome.